A significant decrease in LA dimension and an increase in LVEF were noted.Ĭonclusions: A combination of epicardial and endocardial RF ablation should be considered as a treatment option for patients with persistent and long-standing persistent atrial fibrillation as it is safe and effective in restoring sinus rhythm. Only 1% (1/69) of patients required a repeat ablation for atrial flutter. At 12 months after the procedure 86% (59/69) were in SR and 62.3% (43/69) in SR and off class I/III antiarrhythmic drugs (AADs). Results: At 6 months after the procedure 78% (54/69) of patients were in SR. Patients were scheduled for 3-, 6- and 12-month follow-up with 7-day Holter monitoring. Thirteen patients had LVEF less than 35%. 76-year-old male, past history of paroxysmal atrial fibrillation and atrial flutter, CAD, HTN was brought to the EP lab for ablation procedure of paroxysmal. 64.4% of patients had a history of prior cardioversion or catheter ablation. From 07/2009 to 12.2014, 90 patients with PSAF (n = 39) and LSPAF (n = 51), at the mean age of 54.8 ☙.8, in mean EHRA class 2.6, underwent HABL. Material and methods: The study is a single-center, prospective clinical registry. A single ablation line is created between the inferior vena cava and the tricuspid valve (cavo-tricuspid isthmus ablation) to interrupt the flutter circuit. In 90 of the cases, it is an anti-clockwise circuit, and in 10 of the cases, a clockwise circuit in the right atrium. ![]() ![]() Ablation for Atrial Fibrillation: A Single-Center Experience. Atrial flutter arises from the right atrium. The purpose of this study was to evaluate the procedural safety and feasibility as well as effectiveness of HABL in patients with PSAF and LSPAF 1 year after the procedure. Endoscopy, surgical operative tissue ablation and reconstruction of atria, limited. Introduction: Hybrid ablation (HABL) of atrial fibrillation combining endoscopic, minimally invasive, closed chest epicardial ablation with endocardial CARTO-guided accuracy was introduced to overcome the limitations of current therapeutic options for patients with persistent (PSAF) and longstanding persistent atrial fibrillation (LSPAF).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |